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Colon cancer is still one of themost common causes of cancer in human and is characterized by lymphocyte infiltrates and originates
from the epithelial cells found in the lining of colon or rectum of the gastrointestinal tract. Mesenchymal stem cells (MSCs) are
composed of the multipotent stem cell group of stroma and can be differentiated as various cell lineages, such as fibroblasts,
osteoblasts, and adipocytes. MSCs provide mechanical and structural support and have potential functions during tumor growth
and metastasis. The efficacy of MSC-based therapies is partly dependent on the migration and homing of MSCs to tumors and
metastatic sites. However, their migratory and engraftment potential is poorly understood. In this review, the characteristics and
mechanisms of MSC’s dynamic interaction with colon cancer were summarized, particularly the potential functions of MSCs on
colon cancer, including its role in improving tumor growth and as a potential candidate for tumor therapy. Understanding MSC
homing provides new insights into the manipulation of MSC and the improvement of their efficacy for colon cancer therapy.
1. Introduction
Colorectal cancer (CRC) is one of the most common cancers
diagnosed in humans and is a cause ofmortality in worldwide
[1]. CRC is a complex disease that begins with adenoma,
which occurs through complicated process and reasons. It
was reported that accumulation ofmutations in epithelial and
preneoplastic cells are probably major reasons [2].The causes
of CRC are thought to be linked to a combination of life habits
and genetic factors, such as smoking, aging, diet, and obesity
[3]. In many cases, colon cancer is characterized by lympho-
cyte infiltrates, and the majority of deaths due to CRC are
caused by therapy refractory metastasis [4]. Transformation
of tumor cells and tumor formation are promoted by factors,
including cellular and noncellular components known as the
tumor stroma and tumor environment [5]. The “seed and
soil” theory proposed in 1889 by Stephen Paget explained that
a cancer cell (seed) would only proliferate when the envi-
ronment (soil) is suitable [6]. Thus, the microenvironment is
essential for tumor growth.
The unique microenvironment of colon cancer is com-
posed of many types of cells, such as fibroblasts, immune
cells, and vascular cells [7]. All these cells contribute to
the survival and growth of the tumor. Fibroblasts in the
stroma of various human carcinomas are the important type
of cell resource considered to contribute cancer metastasis
and growth, which can also suppress the anti-tumor immune
response [8–10]. The tumor microenvironment on the colon
cancer cell invasion, metastasis, and resistance against drugs
involves the communication of fibroblasts with cancer cells
directly or indirectly [11, 12]. Especially in colorectal cancer,
direct contact between cancer cells and MSC is rather than
indirect contact [13].Therefore, these cells appear to decrease
the survival prospects of patients. Mesenchymal stem cells
(MSCs) are one of major cellular constituents in intestinal
tumor, which contribute to carcinogenesis via interaction
with other cell types in the tumor environment [14]. As
described by studies, the activities of MSCs during colon
cancer help increase the understanding of their functions
[15, 16]. Mounting evidence shows the suppression function
of microenvironment in tumor growth in vitro, such as
Hela cells (human cervical cancer line), HT29 cells (human
intestinal epithelial cell line), SW480 (human colorectal
adenocarcinoma cell line), Lovo cells (human colorectal ade-
nocarcinoma cell line), and HCT-116 cells (human colorectal
carcinoma cell line) [17–22]. Both the proportion and the
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localization of stromal cells in microenvironments indicate
that the function of these cells is critical to tumor growth and
metastasis [23, 24].
To further explore the role ofMSCs in colon cancer devel-
opment, in this study, the characteristics and mechanisms of
MSC interaction with colon cancer were reviewed, with focus
on the impact of MSCs on colon cancer and howMSCs act as
vehicle for tumor treatment.
2. Characteristics of MSCs
MSCs are nonhematopoietic precursor stem cells with
multiple abilities to differentiate into several types, such
as adipocytes, fibroblasts, osteocytes, and neurocytes [25].
MSCs are originally derived from mesodermal progenitors
and are present in bone marrow, adipose tissue, umbilical
cord, andmuscles [26, 27].Thehallmark of humanMSCs is its
common phenotype expresses CD44, CD73, CD90, CD105,
stromal cell antigen-1, and leukocyte function-associated
antigen-3 and has the following receptors on its surface:
interleukin (II) receptor, 𝛾-interferon receptor, and tumor
necrosis factor 𝛽 (TNF𝛽) receptor, but not FasL, MHC-II
[27, 28]. MSCs can be isolated from different tissues, such as
bone-marrow (BM), adipose tissue (AD), amniotic fluid, and
umbilical cord blood (UCB) [29].
Currently, BM-MSCs, AD-MSCs, and UCB-MSCs are
mainly applied for cancer therapy. Bone-marrow-derived
MSCs are the most commonly used and also the earliest
described MSCs [30]. However, application of BM-MSCs
is limited by their low migration compared with other
MSCs and complex extraction methods [19]. AD-MSCs are
extracted from fat tissues, which are easily obtained, and once
isolated have a similar biological morphology and function
that make them appealing candidates for stem cell transplant
and cancer therapy [31, 32]. USB-MSCs are a group of cells
isolated from the umbilical cord blood of the newborn,
which have a much stronger capacity of proliferation and
continuous culture for more than 80 population doubling
[33, 34]. The utilities of MSCs posed a promising way in
disease therapies due to their properties. They are widely
different from many adult tissues and are easy to apply. They
have a homing ability and they avoid immune rejection.
One of their key properties is target migration. Accompanied
by tissue damage, such as inflammation, injury, or tumor,
MSCs migrate to inflammation sites in vivo. The process of
passing vascular endothelial and basilemma are dominated
by the release of specific endocrinal signals from the tissues
[35, 36]. The tumor tropism capacity of MSCs could be
utilized to deliver antitumor biological agents effectively
and avoid the toxic activity caused by the increase in high
blood concentration [37]. Another feature of MSCs is their
low immunogenicity because of the lack and low levels
of expression of costimulatory molecules proteins, such as
major histocompatibility complex class I (MHC class I)
protein, MHC class II proteins, CD80, and CD86 [38, 39].
3. Homing of MSCs
Homing refers to the phenomenon wherein cells migrate
to the organs through blood circulation or even after long
migration. Studies have reported that MSCs preferentially
migrate to tumor sites [40–42]. The efficacy of MSCs mainly
depends on their ability to produce cytokines, and the hom-
ing of MSCs to tissue requires the secretion of these factors
[43, 44]. A portion of MSC-derived fibroblast premixed with
A375SM melanomas cells was observed to migrate to the
tumor architecture and differentiate into fibrous capsules
[40]. The homing of MSCs is regulated by various factors,
such as age, dosage, and passage of MSCs. The efficiency
of MSCs is attenuated by higher passages and the freshly
isolated MSCs had a better homing capacity [45]. In addition,
the efficiency of MSCs was decreased undergoing a long
culture time, which demonstrated that the decreased potency
of stem cells is due to ageing. MSCs could be derived from
different tissues with differences in the multiple type of
cells isolated [46]. These differences are in part due to the
microenvironment fromwhere they were isolated [47]. Aside
from the source of MSCs, the culture conditions influence
their characteristics.Matrixmetalloproteases (MMPs), which
are known to be crucial to the migration of cells, have
been shown to have an important role in migration. Also,
inflammatory cytokines TNF-𝛼 and TGF-𝛽1 can enhance
migration of MSCs via mediation of MMPs [48, 49].
The homing mechanism of MSCs still keeps elusive.
However, various studies have shown the potential important
role of receptors and adhesion molecules in homing and
migration of MSCs [50–52]. Homing is partly dependent on
the chemokine receptors in tumors while it acts as ligands
for receptors expressed by MSCs and CXCR4 and its partner
was featured in human stem cell homing [53, 54]. Apart from
CXCR4, isolated MSCs also expressed CCR1, CCR4, CCR7,
CCR10, CXCR5, and CXCR6 [55]. Expression of CXCL12
and CXCl2 was increased when rat MSCs were exposed to
a C85 human colorectal cancer cell conditioned medium
[56]. These suggest that chemokines expressed by MSCs
might contribute to the tumor-homing process. Cytokines
secreted by inflammatory as well as tumor, including vascular
endothelial growth factor (VEGF), transforming growth
factor (TGF), neurotrophic factor (NTF), FGFs, CCL2, and
CXCL8 might play a role in the homing of MSCs [55, 57].
Migration and homing of MSCs require cells to attach
to the endothelial cells (ECs) and enter the tumor tissue. A
number of adhesion molecules, such as integrins, involved in
the process of MSCs, interact with ECs [58], while blocking
or knocking out integrins could help in understanding the
role of adhesion molecules in homing of MSCs. Researchers
found that VLA-4/VCAM-1 is needed for the adhesion of
MSCs on ECs, while the binding of MSCs can be suppressed
during VLA-4/VCAM-1 preincubation with antibodies [15].
4. Effect of MSCs on Colon Cancers
4.1. MSCs Enhance Growth and Metastasis of Colon Cancer.
The tumormicroenvironment is important for the promotion
of tumor development. It is reflected by the interaction
of tumor cells and stroma cells adjoining, and is mainly
composed by inflammatory cells and fibroblasts [59, 60].
Studies show that MSCs may be the direct cellular tar-
get of the alterations, which leads to tumor formation,
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which is an important part of the maintenance of tumor
microenvironment [61, 62]. After migration to the tumor
microenvironment,MSCsdifferentiate into tumor-associated
fibroblast (TAF)-like cells, which are a predominate tumor-
promoting stromal cells that affect the survival and growth
of colon cancer [63].These cells exhibit functional properties
and promote tumor cell growth in vitro or in vivo, as
well as the expression of myofibroblast markers (𝛼-smooth
muscle actin and fibroblast surface protein) [64–66]. MSCs
have been reported to exhibit the characteristics of TAFs
reduced by colon cancer cells, and accompanied by high
expression of 𝛼-smooth muscle actin is the transformation of
MSCs to TAFs mediated by Notch signaling through TGF-
𝛽/Smad signaling pathway [20]. In addition, research has
shown that incorporation of KM12SM colon cancer cell and
MSCs with existing carcinoma-associated fibroblast (CAF)
phenotype, such as platelet-derived growth factor receptor-
𝛽 expression, caused enhanced colon cancer cell growth
and metastasis [67]. Collectively, one of the mechanisms
of MSCs that promotes colon cancer cell proliferation is
associated with transforming into myofibroblast in tumor
microenvironment.
Apart from their effect on tumor microenvironment,
MSCs have also been shown to modulate colon cancer cell
growth via other mechanisms. MSCs in colon cancer have
been shown to promote three prospects of tumor, including
angiogenesis or vascular cell formation, tissue invasion and
metastasis, and suppression of apoptosis [18, 22, 67–70]. BM-
MSCs pretreated with inflammatory cytokines IFN-𝛼 and
TNF-𝛼 can induce VEGF expression secreted by colon cancer
cells, and result in the promotion of angiogenesis in vitro
[68]. The transplantation of MSCs and KM12SM caused a
significantly increased number of tumors and decreased the
survival rate of nude mice by enhancing migration and inva-
sion [67]. Hogan et al. [70] found that a higher presence of
MSC-secreted PAI-1 level significantly increased the migra-
tion of HT-29 colon cancer cells. SW480 colon cancer cells
mixed with MSCs transplanted showed elevated capability of
proliferation, rich angiogenesis, and highly metastatic ability
in tumor tissues in vivo [71]. AM-MSC-produced FGF10,
VEGFC, and matrix metalloproteinases (MMPs) increased
the capacity of invasion and formation of colon cancer cells
in vitro through the activation of Wnt signaling pathway and
subsequently increased the tumorigenicity of cancer cells in
murine model in vivo [68]. These demonstrate that MSCs
could enhance growth and metastasis of colon cancer via
various mechanisms.
Accumulating studies have shown results that MSCs
promote colon cancer development. While this may the case,
the effect of MSCs on tumors is still controversial. As noted
in the review of Hogan et al. [70], HT-29 colon cancer cells
were observed to have increased proliferation, while the cell
line HCT-116 showed decreased growth. The result suggests
the dual role of MSCs in colonic tumor. The majority of
tumor models used in the previous studies are performed
by coadministering in an immune-deficient mouse. While
such models have advantages, the defection of autologous
nature and aspects of chronic inflammation induced tumor
is absent.
In the correlation between inflammation and colon can-
cer pathogenesis, it was noted that chronic inflammation
is considered to play a crucial role in colorectal cancer
progression [72]. A clinical study indicated that colon cancer
also tends to develop in patients with inflammatory bowel
disease [73]. Interestingly, the tumor microenvironment is
mainly composed of inflammatory cells and is a necessary
participant in the tumor progression [74]. In contrast with
the promotion of MSCs on colon cancer, studies have
reported the inhibition of MSCs in inflammation [75–78].
IL-1𝛽-primed MSCs can improve inflammatory disorders on
dextran sulfate sodium induced colitis [75]. He et al. (2012)
also proved that allogenic BM-MSCs exert therapeutic effect
on dextran sulfate sodium induced colitis in experimental
mouse model [77].
4.2. MSC as Vehicles for Colon Cancer Therapy. In view of
the tumor migration properties of MSCs, they are modified
to deliver specific anticancer agents to tumor sites [79–81].
ModifiedMSCs are attracted to tumor stroma and, thus, they
can be used to target deliver anti-cancer agents to multiple
sites. Decreased MSC homing to tumor might suppress their
effect on tumor growth. In vivo studies have repeatedly
shown that MSCs are trapped after intravenous injection
[82, 83]. Many existing methods are used to modify MSCs
and the most commonly used are genetically modified MSCs
[84, 85]. The cells can transport the agents into the tumor
microenvironment and greatly reduce the immune reaction
in vivo through high concentration anticancer agents target
tumor site. Using MSCs as delivery vehicle, many researchers
are looking into using their tumor tropic properties to inhibit
tumor development [86–92]. Transfected cytosine deaminase
into AT-MSCs in combination with 5-fluorocytosine can
significantly enhance cytotoxicity on target CT-29 tumor cells
in vitro. In vivo, CD-AT-MSCs administered in mice treated
with 5-fluorocytosine caused inhibition of tumor growth and,
thus, CD-AT-MSCs have the ability to deliver the CD genes
to the tumor site and exert anti-tumor effect [92]. In colon
cancer cell lines HCT-15 and DLD-1, it was found that TNF-
related apoptosis inducing ligand (TRAIL) transgenic human
MSC suppressed colon cancer growth by apoptosis induction
[86]. Although TRAIL-resistant tumor cells exist, Mueller
et al., 2011 [87], proved that, in selected colon cancer cells,
TRAIL-MSC can overcome resistance via direct intercellular
interaction, thereby inhibiting the growth of HCT-8 and
HT29 cells. Moreover, the mechanisms of engineered MSCs
on tumor inhibition could be partly due to the downreg-
ulated expression of VEGF [88]. Transfected MSCs with
sodium iodide symporter and CCL5/RANTES treated mice
showed a significant delay in tumor growth after intrasplenic
injection of the colon cancer cell line LS174t [90]. Different
approaches have been applied for tumor treatment, and with
the depth of our understanding of MSCs, more kinds of
MSC vehicles would be used for colon cancer therapy. Suicide
gene transduced MSCs successfully decreased Rluc activity
in CT26/Rluc cells after prodrug ganciclovir treatment [91].
Different tissue-derived MSCs may have various roles on the
development of colon cancer and may be also influenced by
experimental conditions in vivo or in vitro.
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Recently, studies concerning MSC-derived extracellular
vesicles in the treatment of tumor growth have attracted
a lot of attentions. A large portion effect of MSCs is con-
tributed to their secretion products, such as exosomes [93].
After stimulation, exosomes act in microenvironment and
cellular communication, which is closely related to tumor
formation. In breast cancer cells, exosomes could suppress
angiogensis via downregulation of VEGF expression [94].
Meanwhile, miRNAs transferred by exosomal may promote
the dormancy of the metastatic in breast cancer cells [95, 96].
In addition, TRAIL-expression MSC induced apoptosis in 11
cancer cell lines and had no cytotoxicity in human bronchial
epithelial cells [97]. Collectively, the anticancer activity of
MSC-derived extracellular vesicles might be potential used
in tumor therapy. However, limited studies have been inves-
tigated in colon cancer cells, and more work still needs to be
done for tumor therapy.
The biological effect of MSC on colon cancer is the result
of multiple factors. The source of MSCs is one of important
factor. BM-MSCs and AD-MSCs could enhance colon cancer
growth and metastatic capacity, while UCB-MSCs are less
reported. Another element is the cell type used in vitro. The
effect of MSC secreted PAI-1 on colon cancer cell growth
was cell-line dependent [70]. In addition, the process of
colon carcinogenesis also affects the activity of MSCs. The
anti-inflammatory properties of MSCs make them a tool for
treating colitis-associated colorectal cancer.
MSC could promote colon cancer growth or inhibit
colitis-associated colorectal cancer, and be taken as vehicle
for antitumor agent delivery. One should be careful when
using MSC for drug delivery to patients with malignancies,
as some instances of MSC migration to tumor are not very
efficient because the MSC cannot reach its target site [98].
However, this problem can be addressed by replacing the
paracrine signaling from MSC that affects the tumor [99].
Instead of reducing tumor growth, engineered MSC also can
cause undesired effects; IL-6 secreted by MSCs was shown to
promote breast cancer cell proliferation and migration [100].
Finally, in vitro and in vivo work also have difference [101].
Further research is still needed to reveal the role of MSC and
apply MSC therapy to patients in the clinical setting.
5. Perspectives
Controversies exist in the use of MSCs in colon cancer
treatment. Research on MSC homing and migration could
benefit the MSC-based tumor therapy. What appears to be
an aspect of the target to tumor might have a significant
impact on the efficacy of anti-tumor agents.MSCs engineered
for tumor therapy is advanced, especially in colon cancer
[102, 103]. Many problems on artificial vehicles can be
addressed, such as immune rejection, drug accumulation in
non-target tissues, and poor permeability [104, 105]. MSCs
not only provide a non-immunogenicity delivery system, but
also form a platform for anti-tumor drug delivery [106].
Therefore, targeting treatment with MSCs as a cell carrier
is an excellent approach for colon cancer treatment. Even
the biological characteristics of MSCs are not be influenced
after transfection with adenovirus, retrovirus, and lentivirus
[107, 108]. Gene therapy targeting the tumor based on MSCs
can have an improved therapeutic effect due to the migration
of MSC target to the primary and metastatic tumor sites,
and activation as a mini pump, which continuously pumps
various anti-tumor agents.
Colon cancer is a complex tumor and a significant
advancement inMSC therapy is still limited to the metastatic
disease. At present, engineered MSCs have been applied for
colon cancer treatment [109]. However, the effects of this
treatment have not been validated in vivo in humans. Before
they can be used in the clinic, the manufacturing process with
the most promising evidence should be validated. Moreover,
MSCs are widely studied and applied inmany clinical trials in
various clinical fields, but the exact mechanism underlying
the interaction of MSCs and tumor is little known. Further
works would be helpful for a better understanding of MSC
biology. With the development of cytology, gene therapy, and
stem cell engineering, a simple and easy-work process should
be developed, which might lead to widespread use of MSCs
in efficacious tumor treatment.
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